Lendormin

Brotizolam, the active ingredient in Lendormin, is a benzodiazepine presented as a tablet for oral use. It treats short‑term insomnia in adults. GNH USA supplies Lendormin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Brotizolam acts on the central nervous system to facilitate sleep in patients with insomnia.

Insomnia: short‑term treatment of difficulty falling or staying asleep Sleep onset insomnia: helps initiate sleep quickly Sleep maintenance insomnia: reduces nighttime awakenings

Brotizolam may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness: feeling unusually sleepy during the day - Dizziness: light‑headed sensation or loss of balance - Dry mouth: reduced salivation causing throat discomfort - Headache: mild to moderate pain in the head region - Fatigue: general lack of energy or motivation - Amnesia: difficulty recalling events after taking the medication

Serious or Rare Side Effects: - Respiratory depression: slowed breathing that may be life‑threatening - Dependence or withdrawal syndrome: risk of addiction with prolonged use - Severe allergic reaction: rash, swelling, or difficulty breathing - Depression or suicidal thoughts: mood changes requiring immediate medical attention - Seizures: rare occurrence of convulsive episodes

Before prescribing Brotizolam, clinicians should consider several safety factors.

Avoid alcohol: concurrent use can markedly increase sedation and respiratory depression Use caution in elderly: higher susceptibility to falls and cognitive impairment Do not operate machinery: impaired psychomotor performance may occur Assess renal/hepatic function: dose adjustment may be needed in impairment Pregnancy and lactation: consult a physician as risks are not fully established Store at room temperature: keep in the original pack, protect from moisture.

Brotizolam can interact with other substances that affect the central nervous system.

Major Interactions (Avoid): - CNS depressants (e.g., barbiturates, opioids): additive sedation and respiratory depression - Alcohol: potentiates sedative effects and impairs coordination - Antifungal agents (ketoconazole): may increase Brotizolam plasma concentrations

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (erythromycin, clarithromycin): can raise drug levels modestly - CYP3A4 inducers (rifampicin, carbamazepine): may reduce therapeutic effect - Selective serotonin reuptake inhibitors (SSRIs): may enhance central sedation